Drugs / PEP-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04733027 | May 2021 → Jun 2026 | metastatic malignant neoplasm | Institut Curie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP-010 | “PEP-010 will be administered on days 1, 2 and 3 every week, as a 3-hour intravenous infusion.” NCT04733027 ↗ |
| Route | Intravenous | “PEP-010 will be administered on days 1, 2 and 3 every week, as a 3-hour intravenous infusion.” NCT04733027 ↗ |